<DOC>
	<DOC>NCT01400867</DOC>
	<brief_summary>This is a study of safety, effectiveness, blood levels and tolerance of Ceftaroline fosamil in children with skin infections receiving antibiotic therapy in the hospital.</brief_summary>
	<brief_title>Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections</brief_title>
	<detailed_description>To evaluate safety, effectiveness, pharmacokinetics and tolerance of Ceftaroline fosamil in children who are initially hospitalized with Acute Bacterial Skin and Skin Structure Infections (ABSSSI).</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Cefazolin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Cephalexin</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Male or female, 2 months to &lt; 18 years old. Presence of ABSSSI warranting initial hospitalization. Presence of ABSSSI with measurable margins of erythema, that includes deeper and/or extensive soft tissue involvement, or requires significant therapeutic surgical intervention Documented history of any hypersensitivity or allergic reaction to vancomycin, aztreonam, or any βlactam antimicrobial Uncomplicated skin and soft tissue infections More than 24 hours of prior antimicrobial therapy ≤ 96 hours before randomization. Requirement for any concomitant systemic antimicrobial therapy History of seizures, excluding welldocumented febrile seizure of childhood. Clinical signs or suspicion of meningitis</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Infections</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Teflaro</keyword>
	<keyword>cephalosporin</keyword>
</DOC>